New drug could free patients from daily calcium pills
NCT ID NCT05778071
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests eneboparatide, a lab-made hormone, in 165 adults with chronic hypoparathyroidism. The goal is to see if it can help patients stop taking high-dose calcium and vitamin D supplements while keeping calcium levels normal. Participants receive either the drug or a placebo for 24 weeks, then all receive the drug for up to 132 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eneboparatide (AZP-3601), a synthetic hormone that mimics natural parathyroid hormone
- What this could lead to
- If successful, this treatment could help people with chronic hypoparathyroidism reduce or stop daily calcium and vitamin D supplements, improving their quality of life.
- What could go wrong
- This is a phase 3 trial, but results are not yet known. The drug may not work better than placebo, and side effects could occur. Long-term safety is still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhaus University Hospital
Aarhus, 8200, Denmark
-
Academy of Diabetes, Thyroid and Endocrine
El Paso, Texas, 79935, United States
-
Arthritis Northwest, PLLC
Spokane, Washington, 99204, United States
-
Azienda Ospedaliera Universitaria Careggi
Florence, 50134, Italy
-
Azienda Ospedaliera Universitaria Pisana-Ospedale di Cisanello
Pisa, 56124, Italy
-
Azienda Ospedaliero Universitaria de Bologna, Policlinico Sant Orsola Malpighi
Bologna, 40138, Italy
-
Bone Research and Education Center
Oakville, Ontario, L6M 1M1, Canada
-
CHU de Nantes - Hôtel-Dieu
Nantes, 44093, France
-
CHU de Quebec Research Centre
Québec, G1V 4G2, Canada
-
Cendrum Zdrowi MDM - EB Group Sp.
Warsaw, 00189, Poland
-
Centro Hospital Vila Nova de Faia/Espinho
Porto, 4434-502, Portugal
-
Churchill Hospital
Oxford, OX3 7LE, United Kingdom
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
-
Colombia University Irving Medical Center
New York, New York, 10032, United States
-
Complejo Hospitalario Universitario de A Coruna
A Coruña, 15006, Spain
-
Denver Endocrinology Diabetes and Thyroid Center
Denver, Colorado, 80113, United States
-
Eastern Regional Health Authority Health Sciences Centre
St. John's, Newfoundland and Labrador, A1B 3V6, Canada
-
Eramus MC - University Medical Center
Rotterdam, 3015 GD, Netherlands
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
Milan, 20122, Italy
-
Harbor UCLA Medical Center Endocrinology
Torrance, California, 90502, United States
-
Hopital de la Conception-APHM
Marseille, 13385, France
-
Hospital Bicetre AP-HP
Paris, 94275, France
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
Hospital da Luz Lisboa
Lisbon, 1500-650, Portugal
-
Indiana University (IU) Health University Hospital
Indianapolis, Indiana, 46202, United States
-
Instytut Centrum Zdrowia Matki Polki. Klinika Endokrynologii Chorob Metabolicznych
Lodz, 93-338, Poland
-
Kanazawa University Hospital
Kanazawa, Japan
-
Leiden University Medical Center
Leiden, 2333, Netherlands
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Medicover Neuroendokrinologie MVZ
Munich, 81667, Germany
-
Medycyny Nuklearnej i Chorob Wewnetrznych
Krakow, 30-688, Poland
-
Norfolk & Norwich University NHS Foundation Trust, Quadrum Institute
Norwich, NR4 7UQ, United Kingdom
-
North Shore University Health System
Evanston, Illinois, 60201, United States
-
Northern Nevada Endocrinology
Reno, Nevada, 89511, United States
-
Osaka City Hospital
Osaka, Japan
-
Osaka Metropolital University Hospital
Osaka, Japan
-
Pecsi Tudomanyegyetem
Pécs, 7624, Hungary
-
Physician's East Endocrinology
Greenville, North Carolina, 27834, United States
-
Rigshospitalet
Copenhagen, Denmark
-
Semmelweis Egyetem Belgyogyaszati es Hematologiai Klinika
Budapest, 1083, Hungary
-
Teikyo University Chiba Medical Center
Chiba, Japan
-
The Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania, 19104, United States
-
The Children's Hospital of Philadephia
Philadelphia, Pennsylvania, 19104, United States
-
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
Tokushima University Hospital
Tokushima, Japan
-
Tottori University Hospital
Tottori, Japan
-
Universitaetsklinikum Wuerzburg
Würzburg, 97080, Germany
-
Universitatsklinikum Carl Gustav Carus an der TU Dresden
Dresden, 01307, Germany
-
University Hospitals of Leicester NHS Trust
Leicester, LE1 5WW, United Kingdom
-
University of Chicago - Medical Center
Chicago, Illinois, 60637, United States
-
Via Alvaro del Portillo, 200, Roma, Italy 00128
Roma, 00128, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Testosterone may rebuild strength after spinal cord injury — trial puts it to the test
- Childhood brain tumor survivors face hidden hormone risks years later
- Heart risk in hypoparathyroidism: could a Once-Daily injection protect arteries?
- Could a metabolic modulator help people with type 1 diabetes use insulin better?
- Weekly shot could replace daily needles for kids with growth hormone deficiency
- Weekly shot could replace daily growth hormone injections for children